Presentation is loading. Please wait.

Presentation is loading. Please wait.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Published byGordon Richard Modified over 5 years ago

Similar presentations

Presentation on theme: "A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were."— Presentation transcript:

1 A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were then gated on CD24, considered as TIC. (A) Isotype controls for CD44, CD24, ID8agg control. (B) CD44, CD24 staining on ID8agg control cells. (C) Isotype controls for CD44, CD24, ID8agg PD-L1lo clone 3. (D) CD44, CD24 staining on ID8agg PD-L1lo clone 3 cells. (E) Isotype controls for CD44, CD24, ID8agg PD-L1lo clone 6. (F) CD44, CD24 staining on ID8agg PD-L1lo clone 6 cells.

Download ppt "A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were."

Similar presentations

Fig. 16-CO, p. 449. Fig. 16-1, p. 450 Fig. 16-2, p. 450.

Fig. 16-CO, p Fig. 16-1, p. 450 Fig. 16-2, p. 450.
Isotype control Supplementary Figure S1. Strategy for gating CD11b+CD14-CD33+CD40+ myeloid cells. Singlets were gated from live cells shown in forward.

Isotype control Supplementary Figure S1. Strategy for gating CD11b+CD14-CD33+CD40+ myeloid cells. Singlets were gated from live cells shown in forward.
P. 192. Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.

P Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.
Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.
IFNγIL-2TNFaIL-17A CD40 L MOPP DMSO CD4+ Supplemental figure 5A SEB isotype control isotype control isotype control CD69+ A.

IFNγIL-2TNFaIL-17A CD40 L MOPP DMSO CD4+ Supplemental figure 5A SEB isotype control isotype control isotype control CD69+ A.
Isotype ControlCD126 NA A B Supplementary Figure 1. CD126 expression on CLL cells. (A) A representative FACS plot of the isotype control and CD126 staining.

Isotype ControlCD126 NA A B Supplementary Figure 1. CD126 expression on CLL cells. (A) A representative FACS plot of the isotype control and CD126 staining.
CFSE B16-ova Annexin V 7AAD +Th17 TGF-  1 +Th17 IL-1  +Th17 TGF-  1 +Th17 IL-1  No T cells a EL-4 B16-ova EL-4 CFSE gated Supplementary figure 1 CD25.

CFSE B16-ova Annexin V 7AAD +Th17 TGF-  1 +Th17 IL-1  +Th17 TGF-  1 +Th17 IL-1  No T cells a EL-4 B16-ova EL-4 CFSE gated Supplementary figure 1 CD25.
SSC -A SLAN CD16 CD14 CD3-CD19-CD56 CD123 HLA-DR CD33

SSC -A SLAN CD16 CD14 CD3-CD19-CD56 CD123 HLA-DR CD33
BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden

BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden
BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
Supplementary Figure 2 Anti-PD-L1 (avelumab) enhances CD8 activation and decreases CD4 to a greater extent than commercially available anti-PD-L1 blocking.

Supplementary Figure 2 Anti-PD-L1 (avelumab) enhances CD8 activation and decreases CD4 to a greater extent than commercially available anti-PD-L1 blocking.
% of Suppression a-TGFb (ug/ml) Tr/Tresp 1:1 1:4

% of Suppression a-TGFb (ug/ml) Tr/Tresp 1:1 1:4
A. BCL6 Intensity Score Bin B. CD7 Intensity Score Bin C.

A. BCL6 Intensity Score Bin B. CD7 Intensity Score Bin C.
Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes
Collaboration is required for successful immunotherapy

Collaboration is required for successful immunotherapy
Supplementary figure 1. Gating strategy used for FACS sorting of TIL subsets (CD3+, CD3+CD8+/-, CD3+CD8+PD-1+/-). Two representative fresh tumor samples.

Supplementary figure 1. Gating strategy used for FACS sorting of TIL subsets (CD3+, CD3+CD8+/-, CD3+CD8+PD-1+/-). Two representative fresh tumor samples.
A B C D CD4+ CD8+ Control Isotype Ab Anti-TNFa Ab Control Isotype Ab

A B C D CD4+ CD8+ Control Isotype Ab Anti-TNFa Ab Control Isotype Ab
Reduced endothelial progenitor cells in extracranial arterial stenosis but not intracranial arterial stenosis  Zhixin Huang, MD, PhD, Xiaohao Zhang, MD,

Reduced endothelial progenitor cells in extracranial arterial stenosis but not intracranial arterial stenosis  Zhixin Huang, MD, PhD, Xiaohao Zhang, MD,
A B A B C Supplementary Fig. 8 Supplementary Fig. 9

A B A B C Supplementary Fig. 8 Supplementary Fig. 9
Expression of PD-L1 in mastocytosis

Expression of PD-L1 in mastocytosis

Similar presentations

Ads by Google